Global /United States /Healthcare /Drug Manufacturers - General /MDGL

Madrigal Pharmaceuticals, Inc.

MDGL

• NASDAQ: MDGL • Delayed

518.58USD 0.4%

As of 6 June 2026, Madrigal Pharmaceuticals, Inc. has a market cap of $11.9B USD, ranking #1907 globally and #622 in the United States. It ranks #143 in the Healthcare sector, and #57 in the Drug Manufacturers - General industry.

Global Rank

1907

Country Rank

622

Sector Rank

143

Industry Rank

Key Stats

Market Cap

$11.9BUSD

Enterprise Value

$11.21BUSD

Revenue (TTM)

$958.4MUSD

EBITDA (TTM)

-$298.59MUSD

Net Income (TTM)

-$288.28MUSD

EBITDA Margin

-31%

Profit Margin

-30%

PS Ratio

12.4

PB Ratio

19.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

William Sibold open_in_new

Employees

915

Founded

2011

Website

madrigalpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.4%	-2%	1.5%	4.4%	21%	-11%	57%	66%	284%

News

MDGL Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	MDGL Madrigal Pharmaceuticals Inc ISIN: US5588681057 Shares Out.: Shares Outstanding: 23.056M¹ Shares Float: 21.693M² TV: TradingView: NASDAQ: MDGL SA: Stock Analysis: NASDAQ: MDGL YF: Yahoo Finance: MDGL GF: Google Finance: NASDAQ: MDGL NQ: NASDAQ: MDGL BA: Barron's: MDGL MS: Morningstar: XNAS: MDGL	518.58 USD	TV: TradingView: NASDAQ: MDGL SA: Stock Analysis: NASDAQ: MDGL YF: Yahoo Finance: MDGL GF: Google Finance: NASDAQ: MDGL NQ: NASDAQ: MDGL BA: Barron's: MDGL MS: Morningstar: XNAS: MDGL
London Stock Exchange (LSE / LON) MIC: XLON	0JXI Madrigal Pharmaceuticals Inc ISIN: US5588681057 TV: TradingView: LSE: 0JXI SA: Stock Analysis: LON: 0JXI YF: Yahoo Finance: 0JXI.L GF: Google Finance: LON: 0JXI BA: Barron's: 0JXI MS: Morningstar: XLON: 0JXI	517.35 USD	TV: TradingView: LSE: 0JXI SA: Stock Analysis: LON: 0JXI YF: Yahoo Finance: 0JXI.L GF: Google Finance: LON: 0JXI BA: Barron's: 0JXI MS: Morningstar: XLON: 0JXI
Borsa Italiana (MIL / BIT) MIC: XMIL	1MDGL Madrigal Pharmaceuticals Inc ISIN: US5588681057 TV: TradingView: MIL: 1MDGL SA: Stock Analysis: BIT: 1MDGL YF: Yahoo Finance: 1MDGL.MI GF: Google Finance: BIT: 1MDGL BA: Barron's: 1MDGL MS: Morningstar: XMIL: 1MDGL	463.50 EUR	TV: TradingView: MIL: 1MDGL SA: Stock Analysis: BIT: 1MDGL YF: Yahoo Finance: 1MDGL.MI GF: Google Finance: BIT: 1MDGL BA: Barron's: 1MDGL MS: Morningstar: XMIL: 1MDGL

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 6K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 5K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 3K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 2K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 1K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 888%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 3K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 2K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 2K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$182.72B 1.18T DKK 1K%	11.5	Denmark
Sanofi EPA: SAN	$110.65B 95.26B EUR 830%	19.9	France
GSK plc LSE: GSK	$108.68B 80.96B GBP 814%	14.6	United Kingdom

chevron_leftBack